XM does not provide services to residents of the United States of America.
I
I

Illumina

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Corvex founder Meister sees big upside for stocks already targeted by others

Corvex founder Meister sees big upside for stocks already targeted by others By Svea Herbst-Bayliss NEW YORK, Oct 22 (Reuters) - Activist investor Keith Meister is not embarrassed about lagging behind other corporate agitators, saying his rivals' work has led him to buy companies such as Illumina ILMN.O , Dollar Tree DLTR.O and Fortrea FTRE.O where he argues the stocks are due for big gains.
I
D

U.S. Constellation Energy, Morgan Stanley, Uber

U.S. RESEARCH ROUNDUP-Constellation Energy, Morgan Stanley, Uber Oct 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Morgan Stanley, and Uber, on Thursday. HIGHLIGHTS * Constellation Energy Corp CEG.O : J.P. Morgan initiates coverage with overweight rating * Illumina Inc ILMN.O : HSBC raises to buy from hold * Morgan Stanley MS.N : RBC raises target price to $122 from $108 * Uber UBER.N : Dai
A
A
A
B
B
C
C
C
G
I
S
V
U
U
G
U
W
A
A
C
C
D
D
F
F
P

Bernstein expects a 'not so scary' Q3 for US life sciences firms

BUZZ-Bernstein expects a 'not so scary' Q3 for US life sciences firms ** Brokerage Bernstein expects a "not so scary" Q3 earnings season for U.S. life sciences and tools firms, which "would be a real treat" for investors ** "With the recovery timeline for life science tools continuing to push out (further), some investors feel like they have been t
A
I
T
W

Illumina launches compact, low-cost gene sequencing devices

UPDATE 1-Illumina launches compact, low-cost gene sequencing devices Adds shares and analyst comments in paragraphs 4-5 By Puyaan Singh and Bhanvi Satija Oct 9 (Reuters) - Medical equipment maker Illumina ILMN.O announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to make sequencing accessible to more research and testing labs.
I

Illumina launches compact, low-cost gene sequencing devices

Illumina launches compact, low-cost gene sequencing devices By Puyaan Singh and Bhanvi Satija Oct 9 (Reuters) - Medical equipment maker Illumina ILMN.O on Wednesday announced its new series of smaller, low-cost benchtop gene sequencers, a move that will make sequencing accessible to more research and testing labs. New generation sequencers, like Illumina's MiSeq devices, help determine the sequence of DNA or RNA to study genetic variation associated with diseases and diagnose rare genetic condit
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.